Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008-2012)

Dipika Bansal, Anil Bhagat, Fabrizio Schifano, Kapil Gudala

    Research output: Contribution to journalArticlepeer-review

    10 Citations (Scopus)
    13 Downloads (Pure)

    Abstract

    The present study aimed at systematically reviewing the role and extent of patient-reported outcomes (PROs) usage within the package of scientific evidence considered for marketing authorization (MA). All regulatory information published by the European Medicines Agency (EMA) for products authorized between January 2008 and December 2012 and appearing in the European Public Assessment Report (EPAR) database was examined for efficacy endpoints. The endpoints here considered included: PROs, clinician reported outcomes (CROs), and laboratory reported outcomes (LROs). LROs were the most frequently reported endpoints. Out of the 180 products here selected, 99 (55%), 67 (37%), and 30 (17%), respectively, used LROs, CROs and PROs as primary endpoints (PEs). PROs as any endpoints were used in 82 (46%) products. Out of these, PROs were documented as PE in 30 (37%), with 27 (33%) products having used PROs both as primary and non-PEs. PRO usage was most frequently identified with nervous system and antineoplastic agents. During the study period, the use of all the three types of endpoints appeared to be static. Both the regulatory bodies and the industry should ensure complete and clear reporting of all endpoints used, including PROs, to improve transparency.

    Original languageEnglish
    Pages (from-to)385-395
    Number of pages11
    JournalJournal of Epidemiology and Global Health
    Volume5
    Issue number4
    DOIs
    Publication statusPublished - 29 May 2015

    Keywords

    • European Medicines Agency
    • European Public Assessment Report
    • Health related quality of health
    • Patient reported outcomes

    Fingerprint

    Dive into the research topics of 'Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008-2012)'. Together they form a unique fingerprint.

    Cite this